Literature DB >> 7768619

Convalescent pigs are protected completely against infection with a homologous Actinobacillus pleuropneumoniae strain but incompletely against a heterologous-serotype strain.

T Cruijsen1, L A van Leengoed, M Ham-Hoffies, J H Verheijden.   

Abstract

To study whether Actinobacillus pleuropneumoniae induces a species-specific immunity, we infected pigs in the left lung with serotype 3 or 9 and after 3 weeks we infected their right lungs with serotype 9. Convalescent pigs were protected against homologous strain reinfection, but after heterologous strain reinfection the degree of protection varied. Neutralizing antibodies were not essential for protection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768619      PMCID: PMC173307          DOI: 10.1128/iai.63.6.2341-2343.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Serotype-related differences in production and type of heat-labile hemolysin and heat-labile cytotoxin of Actinobacillus (Haemophilus) pleuropneumoniae.

Authors:  E M Kamp; L A van Leengoed
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

2.  Actinobacillus pleuropneumoniae RTX-toxins: uniform designation of haemolysins, cytolysins, pleurotoxin and their genes.

Authors:  J Frey; J T Bosse; Y F Chang; J M Cullen; B Fenwick; G F Gerlach; D Gygi; F Haesebrouck; T J Inzana; R Jansen
Journal:  J Gen Microbiol       Date:  1993-08

3.  Humoral antibody response and protective immunity in swine following immunization with the 104-kilodalton hemolysin of Actinobacillus pleuropneumoniae.

Authors:  J Devenish; S Rosendal; J T Bossé
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

4.  Endobronchial inoculation of various doses of Haemophilus (Actinobacillus) pleuropneumoniae in pigs.

Authors:  L A van Leengoed; E M Kamp
Journal:  Am J Vet Res       Date:  1989-12       Impact factor: 1.156

5.  Antibody response of swine to outer membrane components of Haemophilus pleuropneumoniae during infection.

Authors:  V J Rapp; R F Ross
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

6.  Mechanisms involved in protection provided by immunization against core lipopolysaccharides of Escherichia coli J5 from lethal Haemophilus pleuropneumoniae infections in swine.

Authors:  B W Fenwick; J S Cullor; B I Osburn; H J Olander
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

7.  Comparison of the cytolysin II genetic determinants of Actinobacillus pleuropneumoniae serotypes.

Authors:  R Jansen; J Briaire; E M Kamp; M A Smits
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

8.  Identification of hemolytic and cytotoxic proteins of Actinobacillus pleuropneumoniae by use of monoclonal antibodies.

Authors:  E M Kamp; J K Popma; J Anakotta; M A Smits
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

9.  Haemophilus parahaemolyticus serotypes. Pathogenicity and cross immunity.

Authors:  R Nielsen
Journal:  Nord Vet Med       Date:  1979-10

10.  Protective efficacy of capsule extracts of Haemophilus pleuropneumoniae in pigs and mice.

Authors:  S Rosendal; O P Miniats; P Sinclair
Journal:  Vet Microbiol       Date:  1986-09       Impact factor: 3.293

View more
  12 in total

1.  Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine.

Authors:  Walaiporn Tonpitak; Nina Baltes; Isabel Hennig-Pauka; Gerald F Gerlach
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Use of an Actinobacillus pleuropneumoniae multiple mutant as a vaccine that allows differentiation of vaccinated and infected animals.

Authors:  Alexander Maas; Ilse D Jacobsen; Jochen Meens; Gerald-F Gerlach
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  Identification of genes transcribed by Actinobacillus pleuropneumoniae in necrotic porcine lung tissue by using selective capture of transcribed sequences.

Authors:  Nina Baltes; Gerald F Gerlach
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  Characterization of the antigenic lipopolysaccharide O chain and the capsular polysaccharide produced by Actinobacillus pleuropneumoniae serotype 13.

Authors:  Leann L MacLean; Malcolm B Perry; Evguenii Vinogradov
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

5.  Field experience with two different vaccination strategies aiming to control infections with Actinobacillus pleuropneumoniae in a fattening pig herd.

Authors:  Marie Sjölund; Per Wallgren
Journal:  Acta Vet Scand       Date:  2010-03-25       Impact factor: 1.695

6.  Specific humoral immune response induced by propionibacterium acnes can prevent Actinobacillus pleuropneumoniae infection in mice.

Authors:  Feng Yang; Qiuyue Ma; Liancheng Lei; Jing Huang; Qun Ji; Ruidong Zhai; Lei Wang; Yu Wang; Linxi Li; Changjiang Sun; Xin Feng; Wenyu Han
Journal:  Clin Vaccine Immunol       Date:  2014-01-15

7.  Identification of Actinobacillus pleuropneumoniae genes important for survival during infection in its natural host.

Authors:  Brian J Sheehan; Janine T Bossé; Amanda J Beddek; Andrew N Rycroft; J Simon Kroll; Paul R Langford
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

8.  Proteomic and immunoproteomic characterization of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae.

Authors:  Falk Fr Buettner; Sarah A Konze; Alexander Maas; Gerald F Gerlach
Journal:  Proteome Sci       Date:  2011-04-20       Impact factor: 2.480

9.  Type IV fimbrial subunit protein ApfA contributes to protection against porcine pleuropneumonia.

Authors:  Lenka Sadilkova; Jiri Nepereny; Vladimir Vrzal; Peter Sebo; Radim Osicka
Journal:  Vet Res       Date:  2012-01-12       Impact factor: 3.683

10.  Association between transmission rate and disease severity for Actinobacillus pleuropneumoniae infection in pigs.

Authors:  Tijs J Tobias; Annemarie Bouma; Angeline J J M Daemen; Jaap A Wagenaar; Arjan Stegeman; Don Klinkenberg
Journal:  Vet Res       Date:  2013-01-11       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.